PMV Pharma FY 2023 net loss $69.0M; rezatapopt Phase 2 on track for Q1 2024

PMV Pharmaceuticals, Inc.

2023-FY EPS reported -$1.44

Cash, cash equivalents, and marketable securities $228.6M at Dec 31, 2023; cost savings from workforce reduction extend runway to end 2026.
Rezatapopt Phase 1 data: confirmed ORR 38% at RP2D (2000 mg daily), median DOR 7 months in TP53 Y220C/KRAS WT patients.
Registrational Phase 2 portion of PYNNACLE trial on track to initiate Q1 2024; FDA alignment on RP2D and key Phase 2 design elements.
Phase 1 analysis in ovarian cancer subgroup selected as late-breaking oral presentation at 2024 SGO Annual Meeting on March 18.
Net loss $69.0M vs $73.3M in 2022; R&D expenses $55.9M, G&A $24.2M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PMV Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023, was $69.0 million compared to $73.3 million for the year ended December 3.

Period: the year ended December 31, 2023
Net income: Net loss for the year ended December 31, 2023, was $69.0 million compared to $73.3 million for the year ended December 3
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2023, was $69.0 million compared to $73.3 million for the year ended December 31, 2022.

View on SEC.gov

22 earnings releases filed in the last 30 days. Browse all earnings releases →

PMV Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-023058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.